N@N

Kennen MacKay Maintained (AGIO) at Buy with Increased Target to $67 on, Feb 25th, 2022

Kennen MacKay of RBC Capital, Maintained "Agios Pharmaceuticals, Inc." (AGIO) at Buy with Increased Target from $61 to $67 on, Feb 25th, 2022.

Kennen has made no other calls on AGIO in the last 4 months.

There are 4 other peers that have a rating on AGIO. Out of the 4 peers that are also analyzing AGIO, 1 agrees with Kennen's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $30 on, Tuesday, February 22nd, 2022

These are the ratings of the 3 analyists that currently disagree with Kennen

---

• Michael King of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $96 on, Thursday, February 24th, 2022
• John Newman of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $44 on, Wednesday, February 16th, 2022
• Greg Harrison of "B of A Securities" Initiated at Strong Buy and Held Target at $54 on, Friday, December 3rd, 2021

Contributing Sources

---